title: Effect of epidermal growth factor on intestinal adaptation after allogeneic small bowel transplantation in rats.
abstract: We reported that epidermal growth factor (EGF) stimulated graft adaptation in a rat model of syngeneic small bowel transplantation. However, graft rejection is a severe problem with clinical small bowel transplantation, because small intestinal wall contains large amounts of lymphoid tissue. Studies were performed to investigate the effect of EGF on allogeneic graft adaptation after small bowel transplantation in rats treated with an immunosuppressant FK506. The transplanted animals received intraperitoneally EGF or saline (untreated) after surgery and were examined for analysis one week later. EGF-treated group markedly enhanced the water absorption and induction of sodium glucose cotransporter (SGLTI) as compared with EGF-untreated group. EGF-treated group also increased the mucosal crypt depth and its cell proliferating rate, although there was no significant difference in the mucosal villus height between the two groups. These results indicate that EGF accelerates intestinal allograft adaptation in part by the recovery of mucosal structure and function after small bowel transplantation in rats. EGF may have relevance to promote graft function in clinical small intestinal transplantation.
authors.affiliation: Second Department of Surgery, Kansai Medical University, Osaka, Japan.
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Kato
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Hamada
authors.forename: Koji
authors.initials: K
authors.lastname: Nakai
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Kitagawa
authors.forename: Seiji
authors.initials: S
authors.lastname: Ito
authors.forename: Tadayoshi
authors.initials: T
authors.lastname: Okumura
authors.forename: Koshiro
authors.initials: K
authors.lastname: Hioki
mesh_terms: D000222:Adaptation, Physiological / Q000187:drug effects*; D000818:Animals; D015153:Blotting, Western; D004347:Drug Interactions; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D006084:Graft Rejection / Q000188:drug therapy; D006085:Graft Survival / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007408:Intestinal Absorption / Q000187:drug effects; D007583:Jejunum / Q000473:pathology / Q000503:physiopathology / Q000637:transplantation*; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis / Q000096:biosynthesis; D009004:Monosaccharide Transport Proteins / Q000032:analysis / Q000096:biosynthesis; D016377:Organ Transplantation; D051381:Rats; D011914:Rats, Inbred BN; D051269:Sodium-Glucose Transporter 1; D016559:Tacrolimus / Q000627:therapeutic use; D014185:Transplantation, Isogeneic
chemical_list: D007166:Immunosuppressive Agents; D008562:Membrane Glycoproteins; D009004:Monosaccharide Transport Proteins; C495676:Slc5a1 protein, rat; D051269:Sodium-Glucose Transporter 1; D004815:Epidermal Growth Factor; D016559:Tacrolimus